The FTC Finds United Health’s OptumRX Is Engaged In Widespread Price Gouging
The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from price gouging.

Pharmacy benefit managers inflated drug prices by $7.3B

 · 2dDealbreaker on MSN
Pharmacy Benefit Managers Not Thrilled With FTC Report Finding Pharmacy Benefit Managers Raise Drug Prices
 · 2dCampus Safety Magazine
FTC: ‘Big 3’ Pharmacy Benefit Managers Engaged in Price Gouging
 · 4dHealthcare Dive
FTC releases second report slamming pharmacy benefit managers
Top three insurers reaped $7.3 billion through their drug middlemen's markups, FTC says
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" prescription price hikes of 1,000% or more.
Modern Healthcare4d
Big 3 PBMs reaped $7.3B from generic specialty drug markups: FTC
The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, OptumRx and Express Scripts.
PBMs made billions marking up specialty drugs by more than 1,000 percent: FTC
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through
How UnitedHealth and Rivals Made $7.3 Billion Marking Up Drugs: FTC
The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension drug.
FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.
STAT4d
FTC slams PBMs for boosting specialty drug prices at the expense of the U.S. health care system
For the second time in less than a year, the FTC has released a highly critical report of pharmacy benefit managers, or PBMs.
FTC finds middlemen inflate specialty generic drug prices by billions of dollars
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs between 2017 and 2022,
soapcentral20h
“Fork found in kitchen” — Netizens react to UnitedHealth reportedly overcharging cancer patients by 1000%
UnitedHealth, the biggest insurance company in America, is receiving backlash after an FTC report revealed that it was overcharging cancer patients by 1000%.
Talk Business1d
Bill would prevent PBMs from dispensing drugs via retail, mail
A bill filed Thursday (Jan. 16) in the Arkansas Legislature would prohibit pharmacy benefit managers and insurance companies from obtaining retail permits and operating pharmacies and mail order services
More Litigation Coming? Insulin MDL Gets Boost from FTC Report
In the report, the FTC said pharmacy benefit managers (PBMs), charge significant markups for cancer, HIV, and other critical specialty generic drugs, marking up the prices of drugs by hundreds and thousands of percent, bringing in an additional $7.3 billion in revenue.